Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro

HER2 is a prognostic and predictive marker widely used in breast cancer. Lapatinib is a tyrosine kinase inhibitor that works by blocking the phosphorylation of the receptor HER2. Its use is related to relatively good results in the treatment of women with HER2+ breast cancer. Thus, this study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Leis-Filho, Antonio Fernando, de Faria Lainetti, Patrícia, Emiko Kobayashi, Priscila, Fonseca-Alves, Carlos Eduardo, Laufer-Amorim, Renée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235449/
https://www.ncbi.nlm.nih.gov/pubmed/34204236
http://dx.doi.org/10.3390/pharmaceutics13060897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235449/
https://www.ncbi.nlm.nih.gov/pubmed/34204236
http://dx.doi.org/10.3390/pharmaceutics13060897

Ejemplares similares